Novelos Therapeutics Announces Positive Phase 2 Results in NOV-002 Neoadjuvant Breast Cancer Trial at Sylvester …
Novelos Therapeutics Announces Positive Phase 2 Results in NOV-002 Neoadjuvant Breast Cancer Trial at Sylvester …
NEWTON, Mass.—-Novelos Therapeutics, Inc. , a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester …
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Doctors Tags: Announces, breast, cancer, Neoadjuvant, NOV002, Novelos, Phase, positive, Results, Sylvester, Therapeutics', Trial
Novelos Therapeutics Discontinues Current Development Program for NOV-002 in NSCLC
Novelos Therapeutics Discontinues Current Development Program for NOV-002 in NSCLC
NEWTON, Mass.—-Novelos Therapeutics, Inc. , a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer with its lead product, NOV-002, in combination with first-line chemotherapy.
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Research Tags: current, Development, Discontinues, NOV002, Novelos, NSCLC, program, Therapeutics'
Novelos Therapeutics’ NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint
Novelos Therapeutics’ NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint
Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial …
Read more on News-Medical-Net